CY1110659T1 - USE TOY SAHA FOR MEDICAL THERAPEUTIC ADMINISTRATION - Google Patents
USE TOY SAHA FOR MEDICAL THERAPEUTIC ADMINISTRATIONInfo
- Publication number
- CY1110659T1 CY1110659T1 CY20101100592T CY101100592T CY1110659T1 CY 1110659 T1 CY1110659 T1 CY 1110659T1 CY 20101100592 T CY20101100592 T CY 20101100592T CY 101100592 T CY101100592 T CY 101100592T CY 1110659 T1 CY1110659 T1 CY 1110659T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical compositions
- saha
- present
- safe
- methods
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αφορά μεθόδους αγωγής καρκίνων, π. χ. μεσοθηλιώματος ή λεμφώματος. Ειδικότερα η παρούσα εφεύρεση αφορά μεθόδους αγωγής μεσοθηλιώματος ή διάχυτου λεμφώματος από μεγάλα Β-κύτταρα (DLBCL), δια χορήγησης φαρμακευτικών συνθέσεων, που περιέχουν αναστολείς HDAC, π.χ. σουμπεροϋλοανιλίδη υδροξαμικού οξέος (SAHA). Οι από του στόματος συνθέσεις των φαρμακευτικών συνθέσεων έχουν ευνοϊκά φαρμακοκινητικά προφίλ, όπως μεγάλη βιοδιαθεσιμότητα και απροσδοκήτως δημιουργούν μεγάλες περιεκτικότητες στο αίμα δραστικών ενώσεων για ένα εξαιρετικό χρονικό διάστημα. Η παρούσα εφεύρεση δίδει επιπλέον μια ασφαλή, ημερήσια δοσολογία θεραπευτικής αγωγής αυτών των φαρμακευτικών συνθέσεων, η οποία είναι εύκολο να ακολουθηθεί, και η οποία έχει ως αποτέλεσμα μια θεραπευτικά αποτελεσματική ποσότητα των αναστολέων HDAC in vivo.The present invention relates to methods of treating cancers, e.g., mesothelioma or lymphoma. More particularly the present invention relates to methods of treating mesothelioma or diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions containing HDAC inhibitors, e.g. hydroxamic acid suboyloylanilide (SAHA). The oral compositions of the pharmaceutical compositions have favorable pharmacokinetic profiles, such as high bioavailability and unexpectedly generate high blood levels of active compounds for an exceptional period of time. The present invention further provides a safe, easy-to-follow, safe, daily dosage regimen of these pharmaceutical compositions that results in a therapeutically effective amount of HDAC inhibitors in vivo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/650,025 US7148257B2 (en) | 2002-03-04 | 2003-08-26 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US10/665,079 US20040127523A1 (en) | 2002-03-04 | 2003-09-16 | Methods of treating cancer with HDAC inhibitors |
| EP04782425A EP1663194B1 (en) | 2003-08-26 | 2004-08-26 | Use of SAHA for treating mesothelioma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110659T1 true CY1110659T1 (en) | 2015-06-10 |
Family
ID=37444418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100592T CY1110659T1 (en) | 2003-08-26 | 2010-06-28 | USE TOY SAHA FOR MEDICAL THERAPEUTIC ADMINISTRATION |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN1870985B (en) |
| CY (1) | CY1110659T1 (en) |
| IS (1) | IS8357A (en) |
| UA (1) | UA83065C2 (en) |
| ZA (1) | ZA200601589B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2349985A2 (en) * | 2008-10-15 | 2011-08-03 | Generics [UK] Limited | Process for the preparation of vorinostat |
| CN103159646B (en) * | 2013-03-19 | 2014-10-22 | 广东药学院 | Hydroxamic acid compound, and preparation method and application thereof |
| CN104292134B (en) * | 2014-10-10 | 2016-06-22 | 广东药学院 | Hydroxamic acid compound and its preparation method and application |
| CN109705057B (en) * | 2017-10-25 | 2023-05-30 | 成都先导药物开发股份有限公司 | Histone deacetylase inhibitor and preparation method and application thereof |
| CN111973590A (en) * | 2020-07-06 | 2020-11-24 | 江苏省人民医院（南京医科大学第一附属医院） | Application of novel HDAC inhibitor LAQ824 in medicine for treating diffuse large B cell lymphoma |
-
2004
- 2004-08-26 CN CN2004800313068A patent/CN1870985B/en not_active Expired - Fee Related
- 2004-08-26 UA UAA200603184A patent/UA83065C2/en unknown
-
2006
- 2006-02-23 ZA ZA200601589A patent/ZA200601589B/en unknown
- 2006-03-17 IS IS8357A patent/IS8357A/en unknown
-
2010
- 2010-06-28 CY CY20101100592T patent/CY1110659T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1870985A (en) | 2006-11-29 |
| IS8357A (en) | 2006-03-17 |
| CN1870985B (en) | 2011-11-30 |
| UA83065C2 (en) | 2008-06-10 |
| ZA200601589B (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006109467A (en) | METHODS FOR TREATING CANCER USING HDAC INHIBITORS | |
| NO20062504L (en) | Compositions and dosage forms for improved absorption | |
| CY1112376T1 (en) | 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists | |
| EA200501849A1 (en) | DERIVATIVES OF PYRAZOLOHINAZOLINE: METHOD FOR OBTAINING AND USING AS KINAZ INHIBITORS | |
| AR059723A2 (en) | COMPOSITION OF HIGH DOSE OF IBANDRONATO | |
| CY1108823T1 (en) | 2-Hydroxy-3-heteroarylindol derivative as inhibitors of GSK3 | |
| EA200600820A1 (en) | METHODS OF TREATMENT, MODIFICATION AND ELIMINATION OF PATIENTS USING 1-OXO-2- (2,6-DIOXOPYPERIDIN-3-IL) -4-METHYLISYNDOLINE | |
| CY1106386T1 (en) | SUBSTITUTED 3-PYRROLIDINE-INDOLE DERIVATIVES | |
| ATE369353T1 (en) | MEDICALLY USABLE ARYLETHANOLAMINE COMPOUNDS | |
| EP1708685A4 (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
| CY1106589T1 (en) | (S)-2-N-PROPYLAMINO-5-HYDROXYTETRALINE AS A D3-ANTIGENT THERAPEUTIC AGENT | |
| NO20055891L (en) | Quinazoline derivatives as aurorakinase inhibitors | |
| CY1110659T1 (en) | USE TOY SAHA FOR MEDICAL THERAPEUTIC ADMINISTRATION | |
| DE602006017728D1 (en) | CANCER TREATMENT BY AGENT AND 2-DEOXYGLUCOSE | |
| UA90893C2 (en) | Oral dosage forms of gemcitabine derivatives | |
| CY1113116T1 (en) | Substituted 4-Aminocyclohexanols | |
| ATE369355T1 (en) | PYRIMIDINAMIDE DERIVATIVES AND THEIR USE | |
| NO20073176L (en) | New drugs for the treatment of respiratory diseases | |
| EA200201044A1 (en) | PHARMACEUTICAL COMPOSITION WITH CONTROLLED SURVIVAL, CONTAINING MIDODRINE AND / OR DESGLIMIDODRINE | |
| CY1107231T1 (en) | Substituted 4-Aminocyclohexanol derivatives | |
| CY1108684T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ASCORBIC ACID FOR THE FUNCTIONAL TREATMENT AND FUNCTIONAL REFERENCES | |
| NO20024673L (en) | Controlled-release pharmaceutical composition for oral use containing midodrine and / or desglymidodrine | |
| SE0203817D0 (en) | New composition | |
| PT1233786E (en) | A PRODUCT CONTAINING AT LEAST AN INHIBITING SUBSTANCE OF THE SYMPTOMS ASSOCIATED WITH AT LEAST AN INHIBITING SUBSTANCE OF PHOSPHOLIPASES A2 FOR THE PREPARATION OF A MEDICATION | |
| HUP0103459A2 (en) | Oral dosage formulations comprising (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid |